Reports FY23 revenue $250,000. “2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease,” commented J.D. Finley, Chief Executive Officer. “As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024. We are looking forward to the advancement of our lead program to bring our product candidates into clinical trials and to increase our value for all stakeholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio to Present at Digestive Disease Week (DDW) 2024
- Palisade Bio’s Corporate Shake-Up Sparks Investor Interest
- Palisade Bio Provides Corporate Update and Reiterates Guidance
- Palisade Bio provides corporate update, reiterated upcoming milestones
- Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members